Valuation : Cipher Pharmaceuticals Inc

Market Cap 360M 260M 223M 209M 191M 24.79B 361M 2.47B 966M 12.5B 975M 954M 41.36B P/E 2026 *
12.6x
P/E 2027 * 11.4x
Enterprise Value 360M 260M 223M 209M 191M 24.79B 361M 2.47B 966M 12.5B 975M 954M 41.36B EV / Sales 2026 *
5.08x
EV / Sales 2027 * 4.35x
Free-Float
57.65%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer - 29/07/2019
Director of Finance/CFO - 10/08/2024
Director of Finance/CFO - 15/08/2022
Director TitleAgeSince
Chairman - 12/06/2019
Director/Board Member 78 21/06/2023
Director/Board Member - 21/06/2023
Change 5-day change 1-year change 3-year change Capi.($)
-22.72%-5.31% - - 260M
-1.12%-5.49%+60.19%+112.43% 1,048B
-1.57%-0.60%+50.33%+59.86% 640B
-1.81%-1.41%+24.07%+75.98% 456B
-0.07%-3.30%+39.16%+40.15% 362B
+0.17%-2.06%+22.91%+37.96% 295B
+0.31%+0.75%+2.26%+12.37% 255B
-0.76%+0.75%+51.75%+70.45% 236B
+1.74%-0.37%-16.46%-53.63% 204B
+0.52%+3.78%+30.67%+93.68% 185B
Average -2.53%-0.72%+29.43%+49.92% 409.07B
Weighted average by Cap. -0.72%-1.92%+38.67%+65.94%

Financials

2026 *2027 *
Net sales 70.88M 51.13M 43.89M 41.09M 37.62M 4.88B 71.08M 487M 190M 2.46B 192M 188M 8.15B 82.69M 59.65M 51.2M 47.94M 43.9M 5.7B 82.93M 568M 222M 2.87B 224M 219M 9.5B
Net income 27.59M 19.9M 17.08M 15.99M 14.64M 1.9B 27.67M 189M 74.03M 958M 74.72M 73.1M 3.17B 32.49M 23.44M 20.12M 18.84M 17.25M 2.24B 32.58M 223M 87.19M 1.13B 88M 86.1M 3.73B
Net Debt - -
Logo Cipher Pharmaceuticals Inc
Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products, manages the required clinical development and regulatory approval process, and markets those products either directly or indirectly in Canada, the United States and South America. The Company's product categories include dermatology, hospital acute care, out‑licensed, and specialty medicine. Its dermatology products include Actikerall, Epuris, Vaniqa and Natroba. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Absorica (isotretinoin) is an oral retinoid. Durela, its specialty medicine, is an opioid analgesic indicated for the management of moderate to moderately severe pain in adults who require continuous treatment for several days or more. Its pipeline products include Piclidenoson CF-101, MOB-015 and DTR-001.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-